Convalescent Plasma Therapy in Immunocompromised Patients Infected With the BA.1 or BA.2 Omicron SARS‐CoV‐2
Influenza and Other Respiratory Viruses · 2024
DOI: 10.1111/irv.13272 ↗Kurz gefasst
Fachartikel in der Zeitschrift Influenza and Other Respiratory Viruses, 2024. Verfasst von Quentin Richier und 21 weiteren Autor:innen. Beteiligte Einrichtung: Service de Maladies Infectieuses, Hôpital Saint-Antoine, AP-HP, Paris, France. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The emergence of SARS‐CoV‐2 Omicron variant has led to a complete reconfiguration of the therapeutic landscape, with all monoclonal antibodies having lost any neutralization activity. We report here a case series of 75 immunocompromised patients infected by the Omicron variant who benefited from COVID‐19 convalescent plasma (CCP). At Day 28, the overall survival was 76% (95% CI 67–86) with no significant difference in the clinical outcome between patients with hematological malignancies, solid organ transplantation or autoimmune diseases. No safety concern was reported during the course of the study. These results showed that CCP is well tolerated and represents a treatment option for immunocompromised patients who remain highly impacted by the COVID19 epidemic.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Service de Maladies Infectieuses, Hôpital Saint-Antoine, AP-HP, Paris, France.
- Sorbonne Université, IPLESP, Inserm UMR-S1136, Paris, France.
- Département de Médecine Interne et Immunologie clinique, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.
- Service de Médecine Interne, Hôpital Foch, Suresnes, France.
- Service des Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.
- INSERM UMR1043, Centre de Physiopathologie de Toulouse-Purpan, Toulouse, France.
ORCID-Profile: Quentin Richier
Zitieren
APA
Richier, Q., De Valence, B., Chopin, D., Gras, E., Levi, L. I., Abi Aad, Y., Pacanowski, J., Meynard, J. L., Plaçais, L., Fey, D., Couture, P., Martin-Blondel, G., Pestre, V., Woessner, J., Ancellin, S., Weyrich, P., Carpentier, B., Idri, S., Tiberghien, P., …, & Lacombe, K. (2024). Convalescent Plasma Therapy in Immunocompromised Patients Infected With the BA.1 or BA.2 Omicron SARS‐CoV‐2. Influenza and Other Respiratory Viruses. https://doi.org/10.1111/irv.13272
Vancouver
Richier Q, De Valence B, Chopin D, Gras E, Levi LI, Abi Aad Y, et al. Convalescent Plasma Therapy in Immunocompromised Patients Infected With the BA.1 or BA.2 Omicron SARS‐CoV‐2. Influenza and Other Respiratory Viruses. 2024. doi:10.1111/irv.13272
BibTeX
@article{Richier2024,
author = {Richier, Quentin and De Valence, Benjamin and Chopin, Dorothée and Gras, Emmanuelle and Levi, Laura I and Abi Aad, Yasmine and Pacanowski, Jérôme and Meynard, Jean-Luc and Plaçais, Léo and Fey, Dorothée and Couture, Priscille and Martin-Blondel, Guillaume and Pestre, Vincent and Woessner, Juliette and Ancellin, Sophie and Weyrich, Pierre and Carpentier, Benjamin and Idri, Salim and Tiberghien, Pierre and Surgers, Laure and Hueso, Thomas and Lacombe, Karine},
title = {Convalescent Plasma Therapy in Immunocompromised Patients Infected With the BA.1 or BA.2 Omicron SARS‐CoV‐2},
journal = {Influenza and Other Respiratory Viruses},
year = {2024},
doi = {10.1111/irv.13272}
}
EUVIMED